021-51111890
购物车（）
sales@molnova.cn
OSU-2S
CAS No. 1351056-65-9
OSU-2S ( OSU 2S )
产品货号. M11419 CAS No. 1351056-65-9
一种非免疫抑制性 FTY720 类似物，PKCδ 激活剂，具有更高的抗增殖效力。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称OSU-2S
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述一种非免疫抑制性 FTY720 类似物，PKCδ 激活剂，具有更高的抗增殖效力。
-
产品描述A non-immunosuppressive FTY720 analogue, PKCδ activator with higher antiproliferative potency with IC50 of 2.4, 2.4, and 3.5 uM in Huh7, Hep3B, and PLC5 cells, respectively; exhibited higher in vitro antiproliferative efficacy relative to FTY720 against HCC cells without cytotoxicity in normal hepatocytes, although devoid of S1P1 receptor activity; induces caspase-dependent apoptosis through ROS-dependent PKCδ activation in HCC tumor cells.
-
体外实验Cell Proliferation AssayCell Line:Hep3B, Huh7, PLC-5, HepG2 cells Concentration:0-10 μM Incubation Time:48 h Result:Showed anti-proliferative effects with IC50s of 2.53, 2.41, 3.96, 1.84 μM for Hep3B, Huh7, PLC-5, HepG2 cells, respectively.Western Blot Analysis Cell Line:Hep3B cells Concentration:1.25, 2.5 μM combinated with sorafenib (2.5, 5 μM)Incubation Time:48 h Result:Decreased the expression of ERK1/2 phosphorylation, increased the expression of PKCδ (38 kDa) when sorafenib/OSU-2S combination.
-
体内实验Animal Model:CD2F1 mice (Hep3B tumor xenograft models)Dosage:5, 10 mg/kg Administration:I.p.; once daily for 42 days Result:Exhibited a higher tumor-suppressive potency, achieving 80% reduction in bioluminescence at the end of treatment.
-
同义词OSU 2S
-
通路Angiogenesis
-
靶点PKC
-
受体PKC
-
研究领域——
-
适应症——
化学信息
-
CAS Number1351056-65-9
-
分子量335.532
-
分子式C21H37NO2
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCCC[C@@](CCC1=CC=C(OCCCCCC(C)C)C=C1)(N)CO.[H]Cl
-
化学全称(S)-2-amino-2-(4-[(6-methylheptyl)-oxy]phenethyl)pentan-1-ol
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Omar HA, et al. Hepatology. 2011 Jun;53(6):1943-58.
2. Mani R, et al. Leukemia. 2015 Feb;29(2):346-55.
3. Mani R, et al. Exp Hematol. 2015 Sep;43(9):770-4.e2.
4. Omar HA, et al. Front Pharmacol. 2016 Nov 30;7:463. eCollection 2016.
产品手册
关联产品
-
ζ-Stat
ze-Stat（1,3,6-萘三磺酸）是一种新型 PKC-zeta (PKC-ze) 特异性抑制剂，IC50 为 5 uM。
-
Ruboxistaurin hydroc...
一种有效、选择性、ATP 竞争性、口服 PKC beta (PKCβ) 抑制剂，对 PKCβ I 和 PKCβ II 的 IC50 分别为 4.7 和 5.9 nM。
-
Pep2m, myristoylated
Cell-permeable, myristoylated form of pep2m. Peptide inhibitor of the interaction between the C-terminus of the GluA2 (AMPA receptor) subunit and N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates AMPA receptor function. Reduces postsynaptic currents in CA1 neurons, AMPA-mediated currents in cultured hippocampal neurons and AMPA receptor surface expression.
